Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A meta-analysis study

Journal of Psychiatric Research

Volumn 83, Issue , 2016, Pages 47-53

  Rocha, Renan Boeira ^a   Dondossola, Eduardo Ronconi ^a   Grande, Antônio José ^a   Colonetti, Tamy ^a   Ceretta, Luciane Bisognin ^a   Passos, Ives C ^b,c   Quevedo, Joao ^a,b,d   da Rosa, Maria Inês ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

BDNF; Electroconvulsive therapy; Major depressive disorder; Meta analysis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

AGE; ARTICLE; COMPARATIVE STUDY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; DEPRESSIVE DISORDER, MAJOR; METABOLISM; PROCEDURES; STATISTICS AND NUMERICAL DATA;

BRAIN-DERIVED NEUROTROPHIC FACTOR; DATABASES, BIBLIOGRAPHIC; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMANS;

EID: 84989906928     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.08.004     Document Type: Article

References (47)

1. Allen, A.P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J. Affect. Disord. 186 (2015 Jul 29), 306–311.
2. Bilgen, A.E., Bozkurt Zincir, S., Zincir, S., Ozdemir, B., Ak, M., Aydemir, E., et al. Effects of electroconvulsive therapy on serum levels of brain-derived neurotrophic factor and nerve growth factor in treatment resistant major depression. Brain Res. Bull. 104 (2014 May), 82–87.
3. Bocchio-Chiavetto, L., Zanardini, R., Bortolomasi, M., Abate, M., Segala, M., Giacopuzzi, M., et al. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur. Neuropsychopharmacol. 16:8 (2006 Dec), 620–624.
4. Brakemeier, E.-L., Merkl, A., Wilbertz, G., Quante, A., Regen, F., Bührsch, N., et al. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biol. Psychiatry 76:3 (2014 Aug 1), 194–202.
5. Brunoni, A.R., Baeken, C., Machado-Vieira, R., Gattaz, W.F., Vanderhasselt, M.-A., BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J. Biol. Psychiatry 15:5 (2014 Jul), 411–418.
6. Bumb, J.M., Aksay, S.S., Janke, C., Kranaster, L., Geisel, O., Gass, P., et al. Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 265:3 (2015 Apr), 227–232.
7. Carvalho, A.F., Berk, M., Hyphantis, T.N., McIntyre, R.S., The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother. Psychosom. 83:2 (2014 Jan), 70–88.
8. Chao, M.V., Rajagopal, R., Lee, F.S., Neurotrophin signalling in health and disease. Clin. Sci. (Lond.) 110:2 (2006 Feb), 167–173.
9. da Costa, S.C., Passos, I.C., Lowri, C., Soares, J.C., Kapczinski, F., Refractory bipolar disorder and neuroprogression. Prog. Neuropsychopharmacol. Biol. Psychiatry 70 (2016 Oct 3), 103–110, 10.1016/j.pnpbp.2015.09.005.
10. Deeks, J.J., Dinnes, J., D'Amico, R., Sowden, A.J., Sakarovitch, C., Song, F., et al. Evaluating non-randomised intervention studies. Health Technol. Assess. 7:27 (2003 Jan), iii–x 1–173.
11. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin. Trials 7:3 (1986 Sep), 177–188.
12. Downs, S.H., Black, N., The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community Health 52:6 (1998 Jun), 377–384.
13. Felice, D., O'Leary, O.F., Cryan, J.F., Dinan, T.G., Gardier, A.M., Sánchez, C., et al. When ageing meets the blues: are current antidepressants effective in depressed aged patients?. Neurosci. Biobehav. Rev. 55 (2015 Aug), 478–497.
14. Gedge, L., Beaudoin, A., Lazowski, L., du Toit, R., Jokic, R., Milev, R., Effects of electroconvulsive therapy and repetitive transcranial magnetic stimulation on serum brain-derived neurotrophic factor levels in patients with depression. Front. Psychiatry, 3, 2012 Jan, 12.
15. Gersner, R., Toth, E., Isserles, M., Zangen, A., Site-specific antidepressant effects of repeated subconvulsive electrical stimulation: potential role of brain-derived neurotrophic factor. Biol. Psychiatry 67:2 (2010 Jan 15), 125–132.
16. Haghighi, M., Salehi, I., Erfani, P., Jahangard, L., Bajoghli, H., Holsboer-Trachsler, E., et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J. Psychiatr. Res. 47:7 (2013 Jul), 908–915.
17. Higgins, J., Green, S., Cochrane handbook for Systematic Reviews of Interventions. 2008.
18. Hu, Y., Yu, X., Yang, F., Si, T., Wang, W., Tan, Y., et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J. ECT 26:2 (2010 Jun), 121–125.
19. Husain, M.M., McClintock, S.M., Rush, A.J., Knapp, R.G., Fink, M., Rummans, T.A., et al. The efficacy of acute electroconvulsive therapy in atypical depression. J. Clin. Psychiatry 69:3 (2008 Mar), 406–411.
20. Husain, M.M., Rush, A.J., Fink, M., Knapp, R., Petrides, G., Rummans, T., et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J. Clin. Psychiatry 65:4 (2004 Apr), 485–491.
21. Inta, D., Lima-Ojeda, J.M., Lau, T., Tang, W., Dormann, C., Sprengel, R., et al. Electroconvulsive therapy induces neurogenesis in frontal rat brain areas. PLoS One, 8(7), 2013 Jan, e69869.
22. Kapczinski, F., Passos, I.C., Wet minds, dry minds, and the future of psychiatry as a science. Acta Psychiatr. Scand. 131:1 (2015 Jan), 7–8.
23. Karege, F., Schwald, M., Cisse, M., Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328:3 (2002 Aug 16), 261–264.
24. Kellner, C.H., Greenberg, R.M., Murrough, J.W., Bryson, E.O., Briggs, M.C., Pasculli, R.M., ECT in treatment-resistant depression. Am. J. Psychiatry 169:12 (2012 Dec), 1238–1244.
25. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62:6 (2005 Jun), 593–602.
26. Lang, U.E., Hellweg, R., Seifert, F., Schubert, F., Gallinat, J., Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol. Psychiatry 62:5 (2007 Sep 1), 530–535.
27. Lin, C.-H., Chen, M.-C., Lee, W.-K., Chen, C.-C., Huang, C.-H., Lane, H.-Y., Electroconvulsive therapy improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients. Neuropsychobiology 68:2 (2013 Jan), 110–115.
28. Lisanby, S.H., Electroconvulsive therapy for depression. N. Engl. J. Med. 357:19 (2007 Nov 8), 1939–1945.
29. Lopez, J.P., Mamdani, F., Labonte, B., Beaulieu, M.-M., Yang, J.P., Berlim, M.T., et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol. Psychiatry 18:4 (2013 Apr), 398–399.
30. Malberg, J.E., Eisch, A.J., Nestler, E.J., Duman, R.S., Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20:24 (2000 Dec 15), 9104–9110.
31. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009 Jan, b2535.
32. Murray, C.J.L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012 Dec 15), 2197–2223.
33. Passos, I.C., Mwangi, B., Cao, B., Hamilton, J.E., Wu, M.-J., Zhang, X.Y., et al. Identifying a clinical signature of suicidality among patients with mood disorders: a pilot study using a machine learning approach. J. Affect. Disord. 193 (2016 Jan 1), 109–116.
34. Passos, I.C., Mwangi, B., Vieta, E., Berk, M., Kapczinski, F., Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr. Scand., 2016 Apr 21.
35. Perera, T.D., Coplan, J.D., Lisanby, S.H., Lipira, C.M., Arif, M., Carpio, C., et al. Antidepressant-induced neurogenesis in the Hippocampus of adult nonhuman primates. J. Neurosci. 27:18 (2007 May 2), 4894–4901.
36. Polyakova, M., Schroeter, M.L., Elzinga, B.M., Holiga, S., Schoenknecht, P., de Kloet, E.R., et al. Brain-derived neurotrophic factor and antidepressive effect of electroconvulsive therapy: systematic review and meta-analyses of the preclinical and clinical literature. PLoS One, 10(11), 2015 Jan, e0141564.
37. Polyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., Schroeter, M.L., BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J. Affect. Disord. 174 (2015 Mar 15), 432–440.
38. Post, R.M., Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J. Psychiatr. Res. 41:12 (2007 Dec), 979–990.
39. Réus, G.Z., Fries, G.R., Stertz, L., Badawy, M., Passos, I.C., Barichello, T., et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300 (2015 May 14), 141–154.
40. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163:11 (2006 Nov), 1905–1917.
41. Salehi, I., Hosseini, S.M., Haghighi, M., Jahangard, L., Bajoghli, H., Gerber, M., et al. Electroconvulsive therapy (ECT) and aerobic exercise training (AET) increased plasma BDNF and ameliorated depressive symptoms in patients suffering from major depressive disorder. J. Psychiatr. Res. 76 (2016 May), 1–8.
42. Scott, A.I.F., Electroconvulsive therapy, practice and evidence. Br. J. Psychiatry 196:3 (2010 Mar), 171–172.
43. Sen, S., Duman, R., Sanacora, G., Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64:6 (2008 Sep 15), 527–532.
44. Stelzhammer, V., Guest, P.C., Rothermundt, M., Sondermann, C., Michael, N., Schwarz, E., et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur. Neuropsychopharmacol. 23:10 (2013 Oct), 1199–1207.
45. Taliaz, D., Nagaraj, V., Haramati, S., Chen, A., Zangen, A., Altered brain-derived neurotrophic factor expression in the ventral tegmental area, but not in the hippocampus, is essential for antidepressant-like effects of electroconvulsive therapy. Biol. Psychiatry 74:4 (2013 Aug 15), 305–312.
46. Tripp, A., Oh, H., Guilloux, J.-P., Martinowich, K., Lewis, D.A., Sibille, E., Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am. J. Psychiatry 169:11 (2012 Nov), 1194–1202.
47. Warden, D., Rush, A.J., Trivedi, M.H., Fava, M., Wisniewski, S.R., The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9:6 (2007 Dec), 449–459.